Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216

Pancreatic cancer is the third most common cause of cancer-related deaths in the United States. Although gemcitabine is the standard of care for most patients with pancreatic cancer, its efficacy is limited by the development of resistance. This resistance may be attributable to the evasion of apoptosis caused by the overexpression of BCL-2 family antiapoptotic proteins. In this study, we investigated the role of BCL-XL in gemcitabine resistance to identify a combination therapy to more effectively treat pancreatic cancer. We used CRISPR-Cas9 screening to identify the key genes involved in gemcitabine resistance in pancreatic cancer. Pancreatic cancer cell dependencies on different BCL-2 family proteins and the efficacy of the combination of gemcitabine and DT2216 (a BCL-XL proteolysis targeting chimera or PROTAC) were determined by MTS, Annexin-V/PI, colony formation, and 3D tumor spheroid assays. The therapeutic efficacy of the combination was investigated in several patient-derived xenograft (PDX) mouse models of pancreatic cancer. We identified BCL-XL as a key mediator of gemcitabine resistance. The combination of gemcitabine and DT2216 synergistically induced cell death in multiple pancreatic cancer cell lines in vitro. In vivo, the combination significantly inhibited tumor growth and prolonged the survival of tumor-bearing mice compared with the individual agents in pancreatic cancer PDX models. Their synergistic antitumor activity is attributable to DT2216-induced degradation of BCL-XL and concomitant suppression of MCL-1 by gemcitabine. Our results suggest that DT2216-mediated BCL-XL degradation augments the antitumor activity of gemcitabine and their combination could be more effective for pancreatic cancer treatment.

[1]  Huan Yang,et al.  Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer , 2021, Clinical Cancer Research.

[2]  Michael Q. Zhang,et al.  Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models , 2021, Clinical Cancer Research.

[3]  S. Zheng,et al.  Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells , 2021, Nature Communications.

[4]  S. Krishnan,et al.  Enhancing efficacy of gemcitabine in pancreatic patient-derived xenograft mouse models , 2020, International journal of pharmaceutics: X.

[5]  Charles R. Thomas,et al.  Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma , 2020, CA: a cancer journal for clinicians.

[6]  O. Takeuchi,et al.  Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2 , 2020, Molecular and Cellular Biochemistry.

[7]  R. Hwang,et al.  Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy , 2020, Cancer Research.

[8]  J. Prados,et al.  The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview , 2019, Cancer biology & medicine.

[9]  A. Ferrando,et al.  A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity , 2019, Nature Medicine.

[10]  Erinna F. Lee,et al.  BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival , 2019, Cell Death & Disease.

[11]  Q. Ye,et al.  GATA1 Promotes Gemcitabine Resistance in Pancreatic Cancer through Antiapoptotic Pathway , 2019, Journal of oncology.

[12]  A. Letai,et al.  Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. , 2019, Blood.

[13]  Sean P. Brown,et al.  Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer. , 2018, Cancer discovery.

[14]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[15]  M. Asselin-Labat,et al.  Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition , 2018, Oncogene.

[16]  J. Kleeff,et al.  Therapeutic developments in pancreatic cancer: current and future perspectives , 2018, Nature Reviews Gastroenterology & Hepatology.

[17]  E. Nakakura,et al.  Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[18]  S. Kasai,et al.  Bcl-2/Bcl-xL inhibitor ABT-737 sensitizes pancreatic ductal adenocarcinoma to paclitaxel-induced cell death. , 2017, Oncology letters.

[19]  T. George,et al.  Orthotopic Patient-Derived Pancreatic Cancer Xenografts Engraft Into the Pancreatic Parenchyma, Metastasize, and Induce Muscle Wasting to Recapitulate the Human Disease , 2017, Pancreas.

[20]  H. Eguchi,et al.  Increased Bcl-xL Expression in Pancreatic Neoplasia Promotes Carcinogenesis by Inhibiting Senescence and Apoptosis , 2017, Cellular and molecular gastroenterology and hepatology.

[21]  S. Wallet,et al.  Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture. , 2016, The American journal of pathology.

[22]  N. Dhomen,et al.  BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors , 2016, Cell Death and Disease.

[23]  Laura H. Tang,et al.  Bcl-xL promotes metastasis independent of its anti-apoptotic activity , 2016, Nature Communications.

[24]  H. Lehr,et al.  Proapoptotic and Antiapoptotic Proteins of the Bcl-2 Family Regulate Sensitivity of Pancreatic Cancer Cells Toward Gemcitabine and T-Cell–mediated Cytotoxicity , 2015, Journal of immunotherapy.

[25]  S. Ramaswamy,et al.  Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer , 2015, Proceedings of the National Academy of Sciences.

[26]  Karen Cichowski,et al.  Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy , 2015, Cell.

[27]  Jun S. Liu,et al.  MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens , 2014, Genome Biology.

[28]  H. Xiong,et al.  Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia , 2014, Cancer Chemotherapy and Pharmacology.

[29]  Manuel Hidalgo,et al.  Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.

[30]  Erin M. Coffee,et al.  mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. , 2014, Cancer discovery.

[31]  Mark A Sussman,et al.  Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. , 2013, Genes & development.

[32]  Travis J Cohoon,et al.  Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. , 2013, Cancer cell.

[33]  S. Lonial,et al.  Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. , 2011, Blood.

[34]  A. Azmi,et al.  Small Molecule Inhibitors of Bcl-2 Family Proteins for Pancreatic Cancer Therapy , 2011, Cancers.

[35]  C. Rudin,et al.  Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  疋田 隼人.  Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver , 2010 .

[37]  R. Kofler,et al.  Noxa: at the tip of the balance between life and death , 2008, Oncogene.

[38]  T. Masui,et al.  Bcl-XL antisense oligonucleotides coupled with antennapedia enhances radiation-induced apoptosis in pancreatic cancer. , 2006, Surgery.

[39]  W. Marasco,et al.  Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. , 2005, Cancer research.

[40]  H. Kalthoff,et al.  Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria‐mediated apoptosis , 2004, International journal of cancer.

[41]  M. Imamura,et al.  Immunohistochemical Analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 Expression in Pancreatic Cancers , 1999, Oncology.